Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

• Drug: Oral PF-06700841 containing 14C microtracer
  Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
• Drug: Oral unlabeled PF-06700841
  60 mg unlabeled PF-06700841 oral dose in 2nd period
• Drug: IV 14C-labeled PF-06700841
  30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period

Exclusion Criteria:

• Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection).
• Total 14C radioactivity measured in plasma exceeding 11 mBq/mL
• History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON®-TB Gold test
• Use of tobacoo/nicotine containing products 3-m prior to dosing or positive urine cotinine test
• Use of herbal supplements within 28 days prior to the first dose of study medication
• Use of prescription or nonprescription drugs (including vitamins and dietary supplements) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen may be used at doses of 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by Pfizer
• Inability to have at least one bowel movement every 2 days on average eGFR of <90 mL/mim/1.73 m2 based on MDRD equation
• Have been vaccinated with live or attenuated live vaccine within the 6 weeks prior to the first dose of investigational product, or expects to be vaccinated with these vaccines during study treatment, or within the 6 weeks following the last dose of investigational product.